146 related articles for article (PubMed ID: 18394010)
1. Hypoxia-inducible factor-2alpha: effect on radiation sensitivity and differential regulation by an mTOR inhibitor.
Bhatt RS; Landis DM; Zimmer M; Torregrossa J; Chen S; Sukhatme VP; Iliopoulos O; Balk S; Bubley GJ
BJU Int; 2008 Aug; 102(3):358-63. PubMed ID: 18394010
[TBL] [Abstract][Full Text] [Related]
2. Reciprocal regulation of hypoxia-inducible factor 2α and GLI1 expression associated with the radioresistance of renal cell carcinoma.
Zhou J; Wu K; Gao D; Zhu G; Wu D; Wang X; Chen Y; Du Y; Song W; Ma Z; Authement C; Saha D; Hsieh JT; He D
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):942-51. PubMed ID: 25585786
[TBL] [Abstract][Full Text] [Related]
3. Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapy.
Holland WS; Tepper CG; Pietri JE; Chinn DC; Gandara DR; Mack PC; Lara PN
Cancer Chemother Pharmacol; 2012 Jan; 69(1):185-94. PubMed ID: 21644050
[TBL] [Abstract][Full Text] [Related]
4. HIF2α acts as an mTORC1 activator through the amino acid carrier SLC7A5.
Elorza A; Soro-Arnáiz I; Meléndez-Rodríguez F; Rodríguez-Vaello V; Marsboom G; de Cárcer G; Acosta-Iborra B; Albacete-Albacete L; Ordóñez A; Serrano-Oviedo L; Giménez-Bachs JM; Vara-Vega A; Salinas A; Sánchez-Prieto R; Martín del Río R; Sánchez-Madrid F; Malumbres M; Landázuri MO; Aragonés J
Mol Cell; 2012 Dec; 48(5):681-91. PubMed ID: 23103253
[TBL] [Abstract][Full Text] [Related]
5. Up-regulation of hypoxia-inducible factor 2alpha in renal cell carcinoma associated with loss of Tsc-2 tumor suppressor gene.
Liu MY; Poellinger L; Walker CL
Cancer Res; 2003 May; 63(10):2675-80. PubMed ID: 12750296
[TBL] [Abstract][Full Text] [Related]
6. Synergistic roles of p53 and HIF1α in human renal cell carcinoma-cell apoptosis responding to the inhibition of mTOR and MDM2 signaling pathways.
Liu QJ; Shen HL; Lin J; Xu XH; Ji ZG; Han X; Shang DH; Yang PQ
Drug Des Devel Ther; 2016; 10():745-55. PubMed ID: 26937175
[TBL] [Abstract][Full Text] [Related]
7. PHGDH as a Key Enzyme for Serine Biosynthesis in HIF2α-Targeting Therapy for Renal Cell Carcinoma.
Yoshino H; Nohata N; Miyamoto K; Yonemori M; Sakaguchi T; Sugita S; Itesako T; Kofuji S; Nakagawa M; Dahiya R; Enokida H
Cancer Res; 2017 Nov; 77(22):6321-6329. PubMed ID: 28951458
[TBL] [Abstract][Full Text] [Related]
8. mTOR in renal cell cancer: modulator of tumor biology and therapeutic target.
Wysocki PJ
Expert Rev Mol Diagn; 2009 Apr; 9(3):231-41. PubMed ID: 19379082
[TBL] [Abstract][Full Text] [Related]
9. The preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-renal cell carcinoma agent.
Xiong Z; Zang Y; Zhong S; Zou L; Wu Y; Liu S; Fang Z; Shen Z; Ding Q; Chen S
Oncotarget; 2017 May; 8(18):30151-30161. PubMed ID: 28404914
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia-inducible factor-2alpha regulates the expression of TRAIL receptor DR5 in renal cancer cells.
Mahajan S; Dammai V; Hsu T; Kraft AS
Carcinogenesis; 2008 Sep; 29(9):1734-41. PubMed ID: 18544564
[TBL] [Abstract][Full Text] [Related]
11. Everolimus resistance in clear cell renal cell carcinoma: miRNA-101 and HIF-2α as molecular triggers?
Nogueira I; Dias F; Morais M; Teixeira AL; Medeiros R
Future Oncol; 2019 Jul; 15(20):2361-2370. PubMed ID: 31267758
[No Abstract] [Full Text] [Related]
12. Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma.
Kuroshima K; Yoshino H; Okamura S; Tsuruda M; Osako Y; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M; Enokida H
Cancer Sci; 2020 May; 111(5):1607-1618. PubMed ID: 32232883
[TBL] [Abstract][Full Text] [Related]
13. Pre-clinical evaluation of AZD-2014, a novel mTORC1/2 dual inhibitor, against renal cell carcinoma.
Zheng B; Mao JH; Qian L; Zhu H; Gu DH; Pan XD; Yi F; Ji DM
Cancer Lett; 2015 Feb; 357(2):468-75. PubMed ID: 25444920
[TBL] [Abstract][Full Text] [Related]
14. Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status.
Nagata Y; Takahashi A; Ohnishi K; Ota I; Ohnishi T; Tojo T; Taniguchi S
Int J Oncol; 2010 Oct; 37(4):1001-10. PubMed ID: 20811722
[TBL] [Abstract][Full Text] [Related]
15. Norcantharidin counteracts acquired everolimus resistance in renal cell carcinoma by dual inhibition of mammalian target of rapamycin complex 1 and complex 2 pathways in Vitro.
Chen X; Cai X; Zheng D; Huang X; Chen Y; Deng T; Mo L; Li H; Li J; Chen S
Anticancer Drugs; 2022 Jan; 33(1):e94-e102. PubMed ID: 34261913
[TBL] [Abstract][Full Text] [Related]
16. HIF2α is involved in the expansion of CXCR4-positive cancer stem-like cells in renal cell carcinoma.
Micucci C; Matacchione G; Valli D; Orciari S; Catalano A
Br J Cancer; 2015 Oct; 113(8):1178-85. PubMed ID: 26439684
[TBL] [Abstract][Full Text] [Related]
17. Loss of VHL and hypoxia provokes PAX2 up-regulation in clear cell renal cell carcinoma.
Luu VD; Boysen G; Struckmann K; Casagrande S; von Teichman A; Wild PJ; Sulser T; Schraml P; Moch H
Clin Cancer Res; 2009 May; 15(10):3297-304. PubMed ID: 19401348
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia inducible factor (HIf1alpha and HIF2alpha) and carbonic anhydrase 9 (CA9) expression and response of head-neck cancer to hypofractionated and accelerated radiotherapy.
Koukourakis MI; Giatromanolaki A; Danielidis V; Sivridis E
Int J Radiat Biol; 2008 Jan; 84(1):47-52. PubMed ID: 17852557
[TBL] [Abstract][Full Text] [Related]
19. Opposite prognostic roles of HIF1α and HIF2α expressions in bone metastatic clear cell renal cell cancer.
Szendrői A; Szász AM; Kardos M; Tőkés AM; Idan R; Szűcs M; Kulka J; Nyirády P; Szendrői M; Szállási Z; Győrffy B; Tímár J
Oncotarget; 2016 Jul; 7(27):42086-42098. PubMed ID: 27244898
[TBL] [Abstract][Full Text] [Related]
20. Upstream signaling inhibition enhances rapamycin effect on growth of kidney cancer cells.
Costa LJ; Gemmill RM; Drabkin HA
Urology; 2007 Mar; 69(3):596-602. PubMed ID: 17382186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
